mLumiOpto Kills Cancer Cells with Targeted Gene Therapy

målinriktad genterapi kan slå ut cancercellernas energicentra och orsaka celldöd i två aggressiva cancertyper: glioblastom och trippelnegativ bröstcancer. — The researchers use nanoparticles to direct the therapy specifically to cancer cells.

A new American study shows that targeted gene therapy can disrupt the energy centers of cancer cells, leading to cell death in two aggressive cancer types: glioblastoma and triple-negative breast cancer.

The researchers use nanoparticles to direct the therapy specifically to cancer cells. In experiments on mice, this has resulted in tumor shrinkage and cell death.

"We disrupt the membrane so that the mitochondria cannot function normally to produce energy or act as signaling hubs," says Lufang Zhou, a professor at Ohio State University and co-author of the study, which was published in the journal Cancer Research.

The technology is called mLumiOpto. It appears promising for treating several difficult-to-treat cancers but has not yet been tested in humans.